Does the media favor BIIB or HALO?

In the previous week, Biogen had 22 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 26 mentions for Biogen and 4 mentions for Halozyme Therapeutics. Biogen's average media sentiment score of 0.98 beat Halozyme Therapeutics' score of 0.88 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 14 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Halozyme Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to HALO or UTHR?

In the previous week, United Therapeutics had 15 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 19 mentions for United Therapeutics and 4 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 0.88 beat United Therapeutics' score of 0.70 indicating that Halozyme Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive United Therapeutics 13 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer INCY or HALO?

In the previous week, Incyte had 7 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 11 mentions for Incyte and 4 mentions for Halozyme Therapeutics. Incyte's average media sentiment score of 0.90 beat Halozyme Therapeutics' score of 0.88 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Halozyme Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NBIX or HALO?

In the previous week, Neurocrine Biosciences and Neurocrine Biosciences both had 4 articles in the media. Halozyme Therapeutics' average media sentiment score of 0.88 beat Neurocrine Biosciences' score of 0.70 indicating that Halozyme Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Halozyme Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer EXEL or HALO?

In the previous week, Exelixis had 4 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 8 mentions for Exelixis and 4 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 0.88 beat Exelixis' score of 0.67 indicating that Halozyme Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 4 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Halozyme Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Halozyme Therapeutics (HALO) Competitors

$69.62 +0.63 (+0.91%)

As of 04:00 PM Eastern

Compare

HALO vs. BIIB, UTHR, INCY, NBIX, and EXEL

Should you buy Halozyme Therapeutics stock or one of its competitors? MarketBeat compares Halozyme Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Halozyme Therapeutics include Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), and Exelixis (EXEL). These companies are all part of the "biotechnology" industry.

How does Halozyme Therapeutics compare to Biogen?

Biogen (NASDAQ:BIIB) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Biogen has higher revenue and earnings than Halozyme Therapeutics. Biogen is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	2.94	$1.29B	$9.32	21.16
Halozyme Therapeutics	$1.40B	5.91	$316.89M	$2.78	25.04

Biogen has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

Biogen currently has a consensus price target of $217.37, suggesting a potential upside of 10.23%. Halozyme Therapeutics has a consensus price target of $81.60, suggesting a potential upside of 17.21%. Given Halozyme Therapeutics' higher possible upside, analysts clearly believe Halozyme Therapeutics is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	12 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.57
Halozyme Therapeutics	1 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.54

87.9% of Biogen shares are owned by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 0.3% of Biogen shares are owned by company insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Biogen had 22 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 26 mentions for Biogen and 4 mentions for Halozyme Therapeutics. Biogen's average media sentiment score of 0.98 beat Halozyme Therapeutics' score of 0.88 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	14 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Halozyme Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Halozyme Therapeutics has a net margin of 23.13% compared to Biogen's net margin of 13.81%. Halozyme Therapeutics' return on equity of 187.91% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	13.81%	12.83%	8.01%
Halozyme Therapeutics	23.13%	187.91%	21.92%

Summary

Halozyme Therapeutics beats Biogen on 9 of the 17 factors compared between the two stocks.

How does Halozyme Therapeutics compare to United Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and United Therapeutics (NASDAQ:UTHR) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

In the previous week, United Therapeutics had 15 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 19 mentions for United Therapeutics and 4 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 0.88 beat United Therapeutics' score of 0.70 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
United Therapeutics	13 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Halozyme Therapeutics has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market.

United Therapeutics has higher revenue and earnings than Halozyme Therapeutics. United Therapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	5.91	$316.89M	$2.78	25.04
United Therapeutics	$3.18B	7.26	$1.33B	$27.09	20.09

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 2.5% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 8.6% of United Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Halozyme Therapeutics presently has a consensus target price of $81.60, suggesting a potential upside of 17.21%. United Therapeutics has a consensus target price of $619.42, suggesting a potential upside of 13.79%. Given Halozyme Therapeutics' higher probable upside, equities analysts plainly believe Halozyme Therapeutics is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.54
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

United Therapeutics has a net margin of 40.62% compared to Halozyme Therapeutics' net margin of 23.13%. Halozyme Therapeutics' return on equity of 187.91% beat United Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	23.13%	187.91%	21.92%
United Therapeutics	40.62%	19.24%	17.25%

Summary

United Therapeutics beats Halozyme Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Halozyme Therapeutics compare to Incyte?

Incyte (NASDAQ:INCY) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

Incyte has a net margin of 26.71% compared to Halozyme Therapeutics' net margin of 23.13%. Halozyme Therapeutics' return on equity of 187.91% beat Incyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	26.71%	26.66%	19.77%
Halozyme Therapeutics	23.13%	187.91%	21.92%

Incyte has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

97.0% of Incyte shares are owned by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 16.2% of Incyte shares are owned by insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Incyte has higher revenue and earnings than Halozyme Therapeutics. Incyte is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	4.06	$1.29B	$7.08	14.75
Halozyme Therapeutics	$1.40B	5.91	$316.89M	$2.78	25.04

In the previous week, Incyte had 7 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 11 mentions for Incyte and 4 mentions for Halozyme Therapeutics. Incyte's average media sentiment score of 0.90 beat Halozyme Therapeutics' score of 0.88 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Halozyme Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Incyte presently has a consensus price target of $106.90, indicating a potential upside of 2.39%. Halozyme Therapeutics has a consensus price target of $81.60, indicating a potential upside of 17.21%. Given Halozyme Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Halozyme Therapeutics is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	14 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.36
Halozyme Therapeutics	1 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.54

Summary

Halozyme Therapeutics beats Incyte on 8 of the 15 factors compared between the two stocks.

How does Halozyme Therapeutics compare to Neurocrine Biosciences?

Neurocrine Biosciences (NASDAQ:NBIX) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

Neurocrine Biosciences has higher revenue and earnings than Halozyme Therapeutics. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$2.86B	5.67	$478.60M	$6.49	24.88
Halozyme Therapeutics	$1.40B	5.91	$316.89M	$2.78	25.04

Neurocrine Biosciences has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

In the previous week, Neurocrine Biosciences and Neurocrine Biosciences both had 4 articles in the media. Halozyme Therapeutics' average media sentiment score of 0.88 beat Neurocrine Biosciences' score of 0.70 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Halozyme Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are held by institutional investors. 4.6% of Neurocrine Biosciences shares are held by company insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Halozyme Therapeutics has a net margin of 23.13% compared to Neurocrine Biosciences' net margin of 21.55%. Halozyme Therapeutics' return on equity of 187.91% beat Neurocrine Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	21.55%	19.79%	13.82%
Halozyme Therapeutics	23.13%	187.91%	21.92%

Neurocrine Biosciences currently has a consensus price target of $187.52, indicating a potential upside of 16.16%. Halozyme Therapeutics has a consensus price target of $81.60, indicating a potential upside of 17.21%. Given Halozyme Therapeutics' higher possible upside, analysts plainly believe Halozyme Therapeutics is more favorable than Neurocrine Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.87
Halozyme Therapeutics	1 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.54

Summary

Halozyme Therapeutics beats Neurocrine Biosciences on 9 of the 16 factors compared between the two stocks.

How does Halozyme Therapeutics compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Exelixis presently has a consensus target price of $47.35, indicating a potential downside of 7.77%. Halozyme Therapeutics has a consensus target price of $81.60, indicating a potential upside of 17.21%. Given Halozyme Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Halozyme Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	9 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.45
Halozyme Therapeutics	1 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.54

In the previous week, Exelixis had 4 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 8 mentions for Exelixis and 4 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 0.88 beat Exelixis' score of 0.67 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	4 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Halozyme Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

Exelixis has higher revenue and earnings than Halozyme Therapeutics. Exelixis is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	5.56	$782.57M	$3.01	17.06
Halozyme Therapeutics	$1.40B	5.91	$316.89M	$2.78	25.04

Exelixis has a net margin of 35.08% compared to Halozyme Therapeutics' net margin of 23.13%. Halozyme Therapeutics' return on equity of 187.91% beat Exelixis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.08%	39.89%	30.23%
Halozyme Therapeutics	23.13%	187.91%	21.92%

85.3% of Exelixis shares are owned by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 2.6% of Exelixis shares are owned by company insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Exelixis beats Halozyme Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Halozyme Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HALO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HALO vs. The Competition

Export

Metric	Halozyme Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.18B	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	25.04	19.75	24.92	23.97
Price / Sales	5.91	329.42	528.81	109.59
Price / Cash	14.46	128.56	44.82	54.51
Price / Book	165.76	8.29	10.79	6.50
Net Income	$316.89M	$23.85M	$3.56B	$336.88M
7 Day Performance	-0.03%	5.21%	1.67%	-0.22%
1 Month Performance	1.90%	2.19%	0.43%	0.77%
1 Year Performance	31.86%	60.99%	32.84%	31.57%

Halozyme Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HALO Halozyme Therapeutics	4.3286 of 5 stars	$69.62 +0.9%	$81.60 +17.2%	+30.6%	$8.18B	$1.40B	25.04	390
BIIB Biogen	3.9134 of 5 stars	$198.64 -0.7%	$216.70 +9.1%	+57.2%	$29.53B	$9.89B	21.31	7,500	Analyst Forecast
UTHR United Therapeutics	4.236 of 5 stars	$549.57 +0.7%	$619.42 +12.7%	+85.1%	$23.17B	$3.18B	20.29	1,400	Insider Trade
INCY Incyte	3.9009 of 5 stars	$101.98 -6.0%	$105.10 +3.1%	+51.4%	$21.68B	$5.14B	14.40	2,844	Analyst Forecast
NBIX Neurocrine Biosciences	3.6752 of 5 stars	$159.51 -0.2%	$187.52 +17.6%	+27.7%	$16.06B	$2.86B	24.58	2,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HALO) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Halozyme Therapeutics (HALO) Competitors

HALO vs. BIIB, UTHR, INCY, NBIX, and EXEL

How does Halozyme Therapeutics compare to Biogen?

Summary

How does Halozyme Therapeutics compare to United Therapeutics?

Summary

How does Halozyme Therapeutics compare to Incyte?

Summary

How does Halozyme Therapeutics compare to Neurocrine Biosciences?

Summary

How does Halozyme Therapeutics compare to Exelixis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HALO vs. The Competition

Halozyme Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Halozyme Therapeutics (HALO) Competitors

HALO vs. BIIB, UTHR, INCY, NBIX, and EXEL

How does Halozyme Therapeutics compare to Biogen?

Which has higher earnings & valuation, BIIB or HALO?

Which has more volatility & risk, BIIB or HALO?

Do analysts rate BIIB or HALO?

Do institutionals and insiders hold more shares of BIIB or HALO?

Does the media favor BIIB or HALO?

Is BIIB or HALO more profitable?

Summary

How does Halozyme Therapeutics compare to United Therapeutics?

Does the media refer more to HALO or UTHR?

Which has more risk and volatility, HALO or UTHR?

Which has better valuation & earnings, HALO or UTHR?

Do insiders & institutionals hold more shares of HALO or UTHR?

Do analysts recommend HALO or UTHR?

Is HALO or UTHR more profitable?

Summary

How does Halozyme Therapeutics compare to Incyte?

Is INCY or HALO more profitable?

Which has more risk & volatility, INCY or HALO?

Do institutionals and insiders have more ownership in INCY or HALO?

Which has higher valuation & earnings, INCY or HALO?

Does the media prefer INCY or HALO?

Do analysts recommend INCY or HALO?

Summary

How does Halozyme Therapeutics compare to Neurocrine Biosciences?

Which has better valuation & earnings, NBIX or HALO?

Which has more risk & volatility, NBIX or HALO?

Does the media favor NBIX or HALO?

Do institutionals & insiders believe in NBIX or HALO?

Is NBIX or HALO more profitable?

Do analysts recommend NBIX or HALO?

Summary

How does Halozyme Therapeutics compare to Exelixis?

Do analysts rate EXEL or HALO?

Does the media prefer EXEL or HALO?

Which has more volatility & risk, EXEL or HALO?

Which has stronger valuation & earnings, EXEL or HALO?

Is EXEL or HALO more profitable?

Do institutionals & insiders believe in EXEL or HALO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HALO vs. The Competition

Halozyme Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools